HC Wainwright & Co. Maintains Buy on enGene Therapeutics, Lowers Price Target to $4
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Andres Y. Maldonado maintains enGene Therapeutics (NASDAQ:ENGN) with a Buy and lowers the price target from $6 to $4.
HC Wainwright & Co. analyst Andres Y. Maldonado maintains enGene Therapeutics (NASDAQ:ENGN) with a Buy and lowers the price target from $6 to $4.